Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Updated daily

Drug recalls

Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.

Class IIOngoingDec 19, 2018Valsartan TabletsCGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.Mylan Pharmaceuticals Inc. · D-0314-2019Class IIOngoingDec 19, 2018Valsartan TabletsCGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.Mylan Pharmaceuticals Inc. · D-0313-2019Class IIOngoingDec 19, 2018Amlodipine and Valsartan TabletsCGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.Mylan Pharmaceuticals Inc. · D-0312-2019Class IIOngoingDec 19, 2018Amlodipine and Valsartan TabletsCGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.Mylan Pharmaceuticals Inc. · D-0311-2019Class IIOngoingDec 19, 2018AmlodipineCGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.Teva Pharmaceuticals USA · D-0310-2019Class IIOngoingDec 19, 2018AmlodipineCGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.Teva Pharmaceuticals USA · D-0309-2019Class IIOngoingDec 19, 2018AmlodipineCGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.Teva Pharmaceuticals USA · D-0308-2019Class IIOngoingDec 19, 2018AmlodipineCGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.Teva Pharmaceuticals USA · D-0307-2019Class IIOngoingDec 19, 2018Amlodipine and Valsartan Tablets 10 mg/320 mgCGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.Teva Pharmaceuticals USA · D-0306-2019Class IIOngoingDec 19, 2018Amlodipine and Valsartan Tablets 5 mg/320 mgCGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.Teva Pharmaceuticals USA · D-0305-2019Class IIOngoingDec 19, 2018Amlodipine and Valsartan Tablets 10 mg/160 mgCGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.Teva Pharmaceuticals USA · D-0304-2019Class IIOngoingDec 19, 2018Amlodipine and Valsartan Tablets 5 mg/160 mgCGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.Teva Pharmaceuticals USA · D-0303-2019Class IITerminatedDec 19, 2018Westminster Irbesartan TabletsCGMP Deviations: FDA laboratory testing confirmed traces of NDEA impurity in specific lots of Irbesartan.Westminster Pharmaceuticals Llc · D-0302-2019Class IITerminatedDec 19, 2018Westminster Irbesartan TabletsCGMP Deviations: FDA laboratory testing confirmed traces of NDEA impurity in specific lots of Irbesartan.Westminster Pharmaceuticals Llc · D-0301-2019Class IITerminatedDec 19, 2018Westminster Irbesartan TabletsCGMP Deviations: FDA laboratory testing confirmed traces of NDEA impurity in specific lots of Irbesartan.Westminster Pharmaceuticals Llc · D-0300-2019Class IITerminatedDec 19, 2018Thyroid PowderCGMP Deviations: Thyroid Powder has inconsistent levels of the active ingredients levothyroxine and liothyronine.LGM Pharma LLC · D-0296-2019Class IIITerminatedDec 19, 2018Norepinephrine 8 mgIncorrect excipient: Product was compounded in 250 mL 5% Dextrose instead of 250 mL 0.9% Sodium ChlorideQuVa Pharma, Inc. · D-0295-2019Class IITerminatedDec 19, 2018Clopidogrel TabletsFailed dissolution specification -Two additional lots being recalled due to Out-of-Specification results observed for dissolution at 18th month stability testing.Dr. Reddy's Laboratories, Inc. · D-0294-2019Class IITerminatedDec 19, 2018FastStat Topical Hemostat Introductory KitcGMP violations noted during the firm's most recent inspection.CAO Group, Inc. · D-0293-2019Class IITerminatedDec 19, 2018BeeGentle Honey Flavored Topical AnestheticcGMP violations noted during the firm's most recent inspection.CAO Group, Inc. · D-0292-2019Class IITerminatedDec 19, 2018SHEER DesenZ Desensitizing TreatmentcGMP violations noted during the firm's most recent inspection.CAO Group, Inc. · D-0291-2019Class IITerminatedDec 19, 2018fas.TRACT Coagulative Hemostatic GelcGMP violations noted during the firm's most recent inspection.CAO Group, Inc. · D-0290-2019Class ITerminatedDec 12, 2018SODIUM CHLORIDE INJECTIONLabeling Not Elsewhere Classified: Fresenius Kabi is taking this action due to an incorrect statement on the product insert for product codes 918610 and 918620...Fresenius Kabi USA, LLC · D-0299-2019Class ITerminatedDec 12, 2018SODIUM CHLORIDE INJECTIONLabeling Not Elsewhere Classified: Fresenius Kabi is taking this action due to an incorrect statement on the product insert for product codes 918610 and 918620...Fresenius Kabi USA, LLC · D-0298-2019Class IIITerminatedDec 12, 2018Amlodipine and Olmesartan Medoxomil TabletsDiscoloration: This product is being recalled due to a confirmed pharmacist report that tablets from this lot were a pink color instead of cream (peach).Aurobindo Pharma USA Inc. · D-0289-2019Class IIITerminatedDec 5, 2018Clindamycin Phosphate Topical Solution USPFailed Impurities/Degradation Specifications; out of specification results observed for other individual impuritiesAkorn, Inc. · D-1208-2019Class IIOngoingDec 5, 2018Sandoz Losartan Potassium and Hydrochlorothiazide TabletsCGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable...Sandoz, Inc · D-0359-2019Class IITerminatedDec 5, 2018Quetiapine Tablets USP 400 mgPresence of Foreign Substance; metal shard found in tabletAscend Laboratories LLC · D-0287-2019Class IITerminatedDec 5, 2018Germ Bloc Health Hand Sanitizer FoamMicrobial Contamination of Non-Sterile Product: Presence of Pseudomonas aeruginosa in productAVKARE Inc. · D-0285-2019Class IIITerminatedDec 5, 2018Nitrofurantoin Monohydrate/Macrocrystals capsulesCross contamination with other products: Product is being recalled due to the potential presence of unrelated ingredients (Benazepril, Haloperidol and Perphenazine).RemedyRepack Inc. · D-0284-2019Class IITerminatedDec 5, 2018INFed (Iron Dextran Injection USP) 100 mg elemental iron/2 mLFailed Stability Specification: out of specification for iron content.Allergan · D-0282-2019Class IITerminatedNov 28, 2018Clopidogrel TabletsFailed Dissolution Specification: Out-of-Specification results were observed for dissolution at 18th month stability testing.Dr. Reddy's Laboratories, Inc. · D-0283-2019Class IITerminatedNov 28, 2018Medi-Stat FoamLabeling: Label mix-up - the label on the product may not match the formula in the bottle.Ecolab Inc · D-0275-2019Class IITerminatedNov 28, 2018Equi-Soft FoamLabeling: Label mix-up - the label on the product may not match the formula in the bottle.Ecolab Inc · D-0274-2019Class IIITerminatedNov 28, 2018Nitrofurantoin Capsules USPCross contamination with other products: This sub-recall is being initiated in support of the recall by the manufacturer (Sandoz) dated 11/1/18, which included lots that...American Health Packaging · D-0273-2019Class IITerminatedNov 28, 2018GSMS Irbesartan TabletsCGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.Sciegen Pharmaceuticals Inc · D-0272-2019Class IITerminatedNov 28, 2018GSMS Irbesartan TabletsCGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.Sciegen Pharmaceuticals Inc · D-0271-2019Class IITerminatedNov 28, 2018GSMS Irbesartan TabletsCGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.Sciegen Pharmaceuticals Inc · D-0270-2019Class IITerminatedNov 28, 2018Westminister Irbesartan TabletsCGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.Sciegen Pharmaceuticals Inc · D-0269-2019Class IITerminatedNov 28, 2018Westminister Irbesartan TabletsCGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.Sciegen Pharmaceuticals Inc · D-0268-2019

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.